The Parker Institute for Cancer Immunotherapy has announced a significant addition to its executive leadership team, appointing Bolyn Hubby as Chief of Staff. The move comes at a pivotal time, as the institute approaches its tenth anniversary and continues to expand its influence in the rapidly evolving field of cancer immunotherapy.
This appointment reflects not only a strengthening of internal leadership but also a broader strategic alignment aimed at accelerating innovation, collaboration, and translational impact across PICI’s network.
Strengthening the Executive Leadership Structure
By bringing Bolyn Hubby into its executive leadership team, PICI signals a clear intention to enhance coordination across its multidisciplinary programs. The role of Chief of Staff within such a complex, research-driven organization extends beyond administrative leadership. It serves as a central node connecting scientific, operational, and strategic priorities.
At an institution built on collaboration between leading academic centers and industry partners, alignment across functions is essential. Hubby’s role is expected to support this integration, ensuring that scientific discoveries are effectively translated into clinical advances.
Two Decades at the Intersection of Science and Strategy
Bolyn Hubby brings more than 20 years of experience across biotechnology sectors, with a career spanning infectious diseases, immunology, and oncology. Her professional trajectory reflects a consistent focus on bridging science with policy, communication, and partnership development.
Most recently, she served as Executive Vice President and Chief Corporate Affairs Officer at Vir Biotechnology. In this role, she led government affairs, corporate communications, and public private partnerships areas that have become increasingly critical in advancing complex therapeutic innovations.
Her earlier work includes leadership roles at Agenovir Corporation, Synthetic Genomics, Liquidia Technologies, and AlphaVax. Across these organizations, she has developed expertise in navigating regulatory environments, shaping external engagement strategies, and building partnerships that accelerate research and development.
A Vision Shared With OncoDaily
In a discussion with OncoDaily, Bolyn Hubby reflected on her new role and the broader direction of the institute, stating:
“I’m honored to join the Parker Institute for Cancer Immunotherapy at such a pivotal moment in its evolution and look forward to advancing its mission by strengthening organizational alignment and accelerating the journey from discovery to meaningful patient impact.”
Her statement underscores a leadership philosophy centered on coordination, translation, and measurable outcomes for patients priorities that align closely with PICI’s collaborative model.
Driving Impact in an Era of Complex Oncology Innovation
Cancer immunotherapy has entered a phase defined by complexity. Advances are no longer limited to single-agent breakthroughs but increasingly involve combination strategies, biomarker-driven approaches, and integrated translational pipelines.
Within this context, leadership roles that connect scientific discovery with operational execution are becoming indispensable. Hubby’s experience positions her to contribute meaningfully to PICI’s mission of transforming immunotherapy research into tangible patient benefit.
Her background in public-private collaboration is particularly relevant, as the future of oncology innovation depends on coordinated efforts across academia, industry, and policy frameworks.
A Personal Mission Rooted in Experience
Beyond her formal remarks, Bolyn Hubby also shared a deeply personal perspective in a recent post on LinkedIn, offering insight into the experiences that have shaped her career in biotechnology and oncology:
“I’m thrilled to share that I’ve joined the Parker Institute for Cancer Immunotherapy as Chief of Staff.
Forty-five years ago, an experimental immunotherapy gave my dad 40 years beyond a metastatic melanoma diagnosis.
My sister is an 11-year cancer survivor. I got into biotech because I’ve seen what breakthroughs can do, and after 20+ years working at the intersection of science, strategy, and execution, PICI is exactly where I want to be.
I’m grateful to Karen Knudsen and the incredible team at PICI for welcoming me into this community of scientists, research institutions, and industry partners who are working toward a future where all cancers become curable. Looking forward to being a part of that future.”
This reflection highlights a motivation that extends beyond leadership and strategy, rooted instead in lived experience and a long-standing commitment to advancing cancer care.
PICI at Ten Years
As the Parker Institute approaches its ten-year milestone, the organization stands at a critical juncture. Over the past decade, it has established itself as a key driver of collaborative cancer research, bringing together leading institutions to accelerate the development of immunotherapy treatments.
The addition of Bolyn Hubby to the leadership team reflects a forward-looking strategy one that emphasizes not only scientific excellence but also the infrastructure and coordination required to sustain long-term impact.
Written by Nare Hovhannisyan,MD